TABLE 2.

LSMeans for the FLU‐PRO total score, SF‐12 PF score, and the EQ‐5D utility score during the RSV‐ARI episode (mES RT‐PCR‐confirmed RSV‐ARI cohort).

Characteristic	RSVPreF3 OA N = 27	Placebo N = 95	LSMean difference (95% CI)	p value
FLU‐PRO total score
N with data	24	76
Baseline a	0.23	0.21
During episode	0.76	0.81	−0.05 (−0.30, 0.20)	0.6956
SF‐12 physical functioning score
N with data	20	69
Baseline	74.15	76.58
During episode	72.16	65.16	7.00 (−9.86, 23.85)	0.4125
EQ‐5D utility score
N with data	19	69
Baseline	0.8616	0.8586
During episode	0.8896	0.8109	0.0786 (−0.0340, 0.1913)	0.1695

Note: A higher FLU‐PRO score indicates a higher level of symptom severity. A higher SF‐12 or EQ‐5D score indicates a higher level of functioning/quality of life.

Abbreviations: CI, confidence interval; EQ‐5D, EuroQol‐5 Dimension; FLU‐PRO, InFLUenza Patient‐Reported Outcome; LSMeans, least squares means, mES, modified exposed set; N, number of first RT‐PCR‐confirmed RSV‐ARI episodes; Placebo, participants receiving placebo; RSV‐ARI, respiratory syncytial virus–acute respiratory infection; RSVPreF3 OA, participants receiving RSVPreF3 OA vaccine; RT‐PCR, reverse transcription polymerase chain reaction; SF‐12 PF, Short Form‐12 physical functioning.

^a Mean score of the assessments at baseline.